ArticleBMC pregnancy and childbirth2025
Prognostic value of antepartum LDH serum levels in predicting adverse maternal outcomes in hypertensive disorders of pregnancy: a prospective cohort study.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertensive disorders of pregnancy (HDP) are a leading cause of maternal mortality, particularly in low-resource settings. While lactate dehydrogenase (LDH) has been proposed as a prognostic biomarker, its clinical utility is limited by a lack of consensus on a standardized threshold for interpretation. This study aimed to evaluate the predictive performance of antenatal LDH for adverse maternal outcomes and establish a clinically applicable cutoff for risk stratification.
methodsThis prospective cohort study included 336 pregnant women with HDP admitted to a national tertiary referral hospital in Vietnam. Serum LDH levels were measured before delivery, and treating clinicians were blinded to the results to prevent performance bias. The primary outcome was a composite of adverse maternal events: eclampsia, HELLP syndrome, placental abruption, acute kidney injury, hepatic injury, pulmonary edema, and maternal death. Multivariate logistic regression and receiver operating characteristic curve analysis were performed to assess associations and predictive performance.
resultsAs a single predictor, LDH demonstrated good overall discrimination for adverse maternal outcomes (AUC = 0.793). In a multivariable logistic regression model, adjusting for proteinuria, highest diastolic blood pressure (DBP), highest systolic blood pressure (SBP), urea, creatinine, maternal age, gravidity, body mass index (BMI), platelets, gestational diabetes mellitus, an LDH level ≥ 254.7 U/L remained a strong and independent predictor of the primary outcome (aOR 9.67; 95% CI 3.29-28.46). Notably, in this high-risk cohort, traditional factors like proteinuria and maternal age were not significant independent predictors in this adjusted model. The multivariable model demonstrated strong internal validity, with all the predictors having a variance inflation factor (VIF) < 5, indicating an absence of multicollinearity and, therefore, stable regression estimates.
conclusionAntepartum LDH level ≥ 254.7 U/L is a strong, independent predictor of adverse maternal outcomes in patients with HDP. These findings, combined with the test's affordability and accessibility, underscore the potential of LDH as a valuable tool for improving risk stratification, particularly in low-resource settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.